Triphase in-licenses clinically enabled oncology assets with high-value potential and develops them in a shared risk model to proof-of-concept, then out-licenses or sells the product to create value.

Triphase has formed a strategic partnership with Celgene Corporation to enable the rapid development of proof of concept in important new cancer therapeutics of mutual interest. Together with the founding organizations, Ontario Institute of Cancer Research (OICR) and MaRS Innovation, and supported by MaRS Phase II Investment Trust, along with strategic oncology partnerships, they form a unique partnership to produce proof-of-concept data for investors, partners, regulators, payers and, ultimately, prescribers and patients.